Home | About PR | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |   Login 
Pharmacognosy Magazine
Search Article 
Advanced search 
Year : 2018  |  Volume : 10  |  Issue : 2  |  Page : 156-160

Effect of UP165, a zea mays leaf extract standardized for 6-methoxybenzoxazolinone, as sleep adjunct

Discovery and Development Department, Unigen, Inc., Seattle, WA, USA

Correspondence Address:
Dr. Mesfin Yimam
Unigen, Inc., 3005 1st Avenue, Seattle, WA 98121
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/pr.pr_148_17

Rights and Permissions

Background: Sleep is a natural phenomenon essential for rejuvenating the body, promoting good health, upholding memory, performance, and maintaining overall health. Its deprivation is linked to the increased health risk that leads to poor quality of life and negative socioeconomic consequences. While behavioral techniques, such as improving sleep hygiene, are typically the first-line of intervention, pharmaceutical drugs are frequently used as adjuncts. However, for most, besides being too expensive, the long-term use of these drugs is marred by their severe adverse side effects and crippling dependency. As a result, significant numbers of patients are always in search for a safe and efficacious alternative from natural sources. Materials and Methods: We evaluated the effects of UP165, a Zea mays (commonly known as corn) leaf extract standardized for 6-methoxybenzoxazolinone content, on sleep latency and sleep time in pentobarbital-induced mouse sleep model. The extract was orally administered at 250 mg/kg (low dose), 500 mg/kg (mid dose), and 1000 mg/kg (high dose) daily for 32 days. The immediate impact of the extract on sleep was also assessed. Results: Increases of 11.6 ± 0.2 (P = 0.008), 10.2 ± 2.4 (P = 0.022), and 10.5 ± 0.9 (P = 0.017) minutes in sleep time were observed for the 250, 500, and 1000 mg/kg UP165 treated mice compared to vehicle control, respectively. Up to 67% sleep latency incidence was observed for mice treated with UP165 compared to the 20% in the vehicle control group. UP165 showed no immediate drowsiness effect. No differences in baseline and end of study bodyweight were observed between groups. Conclusion: UP165 could be used as an adjunct for a sleep disorder. Abbreviations used: UP165-Maizinol, 6-MBOA-6-methoxybenzoxazolinone, SAMe-S-Adenosyl Methionine, GABA-gamma-aminobutyric acid, SK2 channel-Small conductance calcium-activated potassium channels.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded104    
    Comments [Add]    

Recommend this journal